Takeda Adds To Oncology Holdings By Purchasing Intellikine And Two PI3K Clinical Candidates
This article was originally published in PharmAsia News
Executive Summary
Takeda’s Millennium oncology unit will absorb Intellikine’s programs in a deal paying $190 million upfront to buy out the privately held biotech.
You may also be interested in...
Infinity In-Licenses Portfolio Of PI3 Kinase Inhibitors For Inflammatory Diseases
Deal is the historically oncology-focused Infinity's first pipeline-building move since it began a strategic alliance with Purdue Pharma and the latter's European affiliate Mundipharma in late 2008.
Intellikine Inc.
Intellikine is developing a group of compounds capable of selectively inhibiting different PI3K isoforms. It can mix and match components to achieve a variety of therapeutic goals. The company's lead program, an mTOR inhibitor for cancer, is nearing the clinic. The start-up also sees significant potential for its PI3 kinase inhibitors in inflammatory diseases and hopes to begin a Phase I trial in that area next year.
Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage
Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. In this case study, Scrip takes a deep dive into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.